Navigation Links
Intarcia Appoints Raymond Keane Vice President, General Counsel, And Chief Legal Officer
Date:9/9/2013

BOSTON, Sept. 9, 2013 /PRNewswire/ -- Intarcia Therapeutics, Inc. today announced the appointment of Raymond T. Keane, Esq. to the position of Vice President, General Counsel and Chief Legal Officer. In this newly created position, Mr. Keane will report directly to Kurt Graves, Intarcia Chairman, President, and CEO. In his new role, Mr. Keane will play an important part in the growth and development of the company as an integrated biopharmaceutical enterprise, and specifically in the company's efforts to advance its lead candidate through the FREEDOM Phase 3 clinical trial program and on toward global commercialization in type 2 diabetes.

"Ray is a great talent who will be an invaluable contributor to our business goals and a key advisor to both our senior leadership team and our Board of Directors as we rapidly advance our business," said Mr. Graves. "In this new position of General Counsel, I see Ray as a sort of 'Renaissance Man' due to his uncommon breadth of insight and the versatility of his skills. It's that sort of transformational thinking that helps create the forward strength of Intarcia, and it is absolutely consistent with how we've strengthened and built up our entire leadership team this year. Although a Chief Legal Officer is not a function where these attributes are typically seen, it is one where I do not want to see them absent. We are very excited Ray has joined our team."

Throughout his career, Mr. Keane has participated in the global launch of eight small molecule and biologic therapies, has led corporate diligence that resulted in raising more than $700 million, and has built both U.S. and European legal groups from the ground up. He also provided legal leadership throughout the evolution of ARIAD Pharmaceuticals from a research and development platform to a fully integrated global commercial organization, and worked his way up to being Chief Counsel to the head of global marketing at Bristol-Myers Squibb.

Before joining Intarcia, Mr. Keane served as Senior Vice President, General Counsel, Secretary, and Chief Compliance Officer of ARIAD Pharmaceuticals. Prior to ARIAD, he contributed for 20 years at levels of increasing responsibility at Bristol-Myers Squibb Company (BMS). Mr. Keane's tenure at BMS began as an Assistant Counsel in corporate litigation and ultimately ascended to Senior Counsel, Worldwide Medicine. In this latter position, he had legal responsibility for the global commercialization of three new drugs/biologics and legal oversight of global marketing strategy, launch campaigns, corporate communications, healthcare professional interactions, and worldwide strategic development. Before joining BMS, Mr. Keane was an associate with the law firm of Wilson, Elser, Moskowitz, Edelman & Dicker, and was also an associate with Martin, Clearwater and Bell. He received his J.D. from Fordham University School of Law and his B.A. in Economics from Fordham University.

About ITCA 650
ITCA 650 (a once- or twice-yearly continuous subcutaneous delivery of exenatide) is being developed by Intarcia for the treatment of type 2 diabetes. The investigational therapy employs Intarcia's proprietary technology platform involving a matchstick-size, miniature osmotic pump that is inserted subcutaneously to provide continuous and consistent drug therapy, and the company's proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for extended periods of time.

Data from Intarcia's ITCA 650 Phase 2 program have demonstrated significant and sustained reductions in HbA1c and body weight over 48 weeks of treatment with a marked reduction in the GI adverse events typically associated with the self-injection products in this class. ITCA 650 is an investigational new therapy and is not currently approved by any regulatory authority. Exenatide, the active agent in ITCA 650, is a glucagon-like peptide-1 (GLP-1) receptor agonist currently marketed globally as twice-daily and once-weekly self-injection therapies for type 2 diabetes. Upon approval, ITCA 650 would represent the first injection-free GLP-1 therapy that can deliver up to a full year of treatment from a single placement. Intarcia's robust intellectual property portfolio protects ITCA 650 through 2031.

About Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. is a biopharmaceutical company developing therapies to enhance treatment outcomes by optimizing and improving the efficacy, continuous administration and tolerability of drug therapies. In addition, delivering medicines just once or twice yearly virtually ensures patient adherence and compliance, which is very poor in most chronic diseases. Intarcia's drug development expertise and competitive edge are demonstrated by its abilities to stabilize proteins and peptides at above-body temperature and to deliver them in a constant and consistent manner via Intarcia's proprietary technology platform. Intarcia is pursuing a Phase 3-stage development program for type 2 diabetes and has additional programs ongoing for weight regulation to control obesity. For more information on the Company, please visit www.intarcia.com.

Intarcia and its logo are registered trademarks of Intarcia Therapeutics, Inc.


'/>"/>
SOURCE Intarcia Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Intarcia Appoints Owen Hughes Chief Business Officer and Head of Corporate Development
2. Intarcia Enrolls First Patients in "FREEDOM" Global Phase 3 Program for ITCA 650 in Type 2 Diabetes
3. Intarcia Supports American Diabetes Association Call For Independent Review Of Incretin-Based Therapies
4. Intarcia Therapeutics Appoints Gino Santini To Its Board Of Directors
5. Winner Medicals Special Committee Appoints Independent Financial Advisor and Retains Legal Counsel
6. Pro-Dex, Inc. Appoints Michael J. Berthelot Chief Executive Officer
7. Nephros Appoints John C. Houghton as President and Chief Executive Officer
8. Elsevier Appoints New President of Elsevier CPM Resource Center
9. GenWay Biotech Appoints New Vice President of Custom/OEM
10. Angeion Appoints Matthew S. Margolies as Executive Vice President - Global Sales
11. Althea Technologies Appoints Dr. Kristin DeFife, Director, Biologics Manufacturing And Jack Wright, VP, Sales and Marketing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... 2016 Tie-up with Government hospitals ... to save newborns   Fortis La Femme, ... in collaboration with Breast Milk Foundation (BMF), a non-profit organization ... Milk Bank, ,Amaara, in Delhi-NCR today. This non-profit centre recognizes ... infants and should be available to babies deprived of mother,s ...
(Date:4/27/2016)... SAN FRANCISCO , April 27, 2016 /PRNewswire/ ... to reach over USD 2.14 billion by 2022, ... Research, Inc.       (Logo: http://photos.prnewswire.com/prnh/20150105/723757 ... key technological advancement affecting the efficiency and accuracy ... hence, the persistent demand for novel urinalysis instruments ...
(Date:4/26/2016)... US demand for infection prevention products ... annually to $27.6 billion in 2020.  Increasing pressures ... rates of healthcare-associated infections (HAIs) will boost revenues ... Although declining, the overall rate of certain HAIs ... by the CDC.  Recent statistics indicate that only ...
Breaking Medicine Technology:
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... ... closing of a growth round of funding led by Eastside Partners, with participation ... the company’s rapidly growing customer base and accelerate its technology and product roadmap. ...
(Date:4/29/2016)... ... ... Regenerative Medicine Solutions (RMS) scored 94.8124 out of 100 on Tampa ... for Tampa’s Best Places to Work. They were ranked in the Big Category, which ... our team,” says RMS Human Resources Manager Irene Miller. “We work hard to build ...
(Date:4/29/2016)... ... ... The infertility specialists at HRC Fertility/Orange County (HRC/OC) -- Dr. Mickey S. ... are proud of the recent release of their 2014 in vitro fertilization success rates ... the latest verified data for 375 U.S. member clinics. *Preliminary data shows HRC/OC achieved ...
(Date:4/29/2016)... ... April 29, 2016 , ... Natren, Inc. recently ... of probiotics, Petbiotics ™, as they fondly call them. As animal lovers, ... networking for their non-profit organizations. Animal rescues across the nation face huge hurdles ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... outsourced billing and coding services, and Deyta Analytics, recently announced the recipients of ... highest level of quality as measured from the caregiver’s point of view. The ...
Breaking Medicine News(10 mins):